Incept BioSystems is gearing up to become Ann Arbor’s next start-up success story if only it can get out of the incubation stage.

The University of Michigan spin-off employs seven people downtown, but hopes to double that number within the next year when it commercializes its first product. The company, founded in 2005, is trying to reset the industry standard for in-vitro fertilization.

"We will be providing a superior method for embryonic development used for in-vitro fertilization therapy," says Chris Bleck, CEO of Incept BioSystems. That loosely translates to helping significantly increase the success rate of in-vitro fertilization for mothers trying to have babies.

Incept BioSystems is in the final stages of developing its product. It hopes to start human clinical trials this year and submit for FDA approval before the end of the year. Commercialization will happen so after, which will mean more jobs in manufacturing, quality assurance, sales and marketing.

The company was recently named as one of Michigan's 50 Companies to Watch by the Edward Lowe Foundation.

Source: Chris Bleck, CEO of Incept BioSystems
Writer: Jon Zemke